Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Harrow, Inc.
Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
October 10, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Relaunches TRIESENCE®
October 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Nashville Expansion
September 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Three Investor Conferences in September in New York
September 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Second Quarter 2024 Financial Results
August 07, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024
July 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Attend 2024 ASRS Annual Meeting
July 12, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products
July 09, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Provides TRIESENCE® Relaunch Update
June 20, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
June 05, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Two Investor Conferences in May
May 15, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces First Quarter 2024 Financial Results
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
May 13, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
April 25, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
March 19, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
March 05, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
February 15, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces New Appointments to its Board of Directors
January 29, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
January 11, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Partners with Leading Healthcare Market Access Technology Platforms
January 03, 2024
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Completes Transfer of the TRIESENCE® New Drug Application
November 29, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow to Present at Two Investor Conferences in November
November 20, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Announces Third Quarter 2023 Financial Results
November 13, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
October 30, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
October 24, 2023
From
Harrow, Inc.
Via
Business Wire
Tickers
HROW
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright